Commercializing the first rapid, accurate in vitro diagnostic (IVD) test that prognosticates the onset of sepsis and severe sepsis based upon our patented monoclonal antibodies and immunoassay methods for plasma iNOS is only the first step for R&D Ab®. Our on-going research and development projects continue to produce new and exciting results that can be applied to other underserved clinical diagnostic market segments. Our aim is to transition our novel research findings out of the laboratory and into new clinical products for the easier diagnosis of additional inflammatory pathologies. Further, our independent research and development projects continue to identify unique biomarkers that can be used to diagnose other underserved clinical pathologies especially cancer diagnostics and companion diagnostics for new therapeutics. Our aim is to develop, patent, and commercialize clinical diagnostic tests based upon our original discoveries of these novel biomarkers.

Future In Vitro Diagnostic tests

  • Clinical laboratory Auto-Analyzer test for sepsis
  • Point-of-Care device for sepsis and severe sepsis
  • Flow cytometry clinical test for sepsis
  • Future In Vitro Diagnostic Test Products for other inflammatory conditions
    • Rheumatoid arthritis
    • Inflammatory bowel disease
      • Ulcerative colitis
      • Crohn’s disease
    • Transplant and graft rejection
  • New In Vitro Diagnostic Tests for other underserved clinical diagnostic markets
    • Patents for additional unique biomarkers as cancer diagnostics
    • Patents for novel diagnostic methods
  • Companion diagnostics for new therapeutics
Home | News | R&D Vision | President's Message | Achievements | Leadership Team | Technology | Contact